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ABSTRACT:  The amyloid plaques associated with Alzhei-
mer's disease (AD) comprise fibrillar amyloid-β (Aβ) peptides 
as well as non-protein factors including glycosaminoglycan 
(GAG) polysaccharides. GAGs affect the kinetics and path-
way of Aβ self-assembly and can impede fibril clearance and 
therefore may be accessory molecules in AD.  Here we report 
the first high-resolution details of GAG-Aβ fibril interactions 
from the perspective of the saccharide. Binding analysis indi-
cated that the GAG proxy heparin has a remarkably high 
affinity for Aβ fibrils with 3-fold cross-sectional symmetry 
(3Q).  Chemical synthesis of a uniformly 13C-labeled octasac-
charide heparin analog enabled magic-angle spinning solid-
state NMR (SSNMR) of the GAG bound to 3Q fibrils, and 
measurements of dynamics reveal a tight complex in which all 
saccharide residues are restrained without undergoing sub-
stantial conformational changes.  Intramolecular 13C-15N di-
polar dephasing is consistent with close (< 5 Å) contact be-
tween GAG anomeric position(s) and one or more histidine 
residues in the fibrils. These data provide a detailed model for 
the interaction between 3Q-seeded Aβ40 fibrils and a major 
non-protein component of AD plaques, and reveal that GAG-
amyloid interactions display a range of affinities that critically 
depend on the precise details of the fibril architecture.  
Alzheimer’s disease (AD) is characterized pathologically by the 
accumulation of insoluble plaques within the extracellular spaces 
of brain tissue.  The main protein constituents of AD plaques are 
the 40- and 42-residue amyloid-β peptides, Aβ40 and Aβ42, de-
rived from the amyloid precursor protein. The relationship be-
tween Aβ self-assembly and disease has not been elucidated, but 
the development of drugs that lower the propensity of Aβ peptides 
to self-assemble or reduce the aggregate concentration is a thera-
peutic goal.1 Aβ amyloid plaques in the brain are highly heteroge-
neous, comprising fibrous proteins of different structural organi-
sations2, metal ions, nucleic acids and glycosaminoglycans 
(GAGs),3 the linear sulfated polysaccharide components of prote-
oglycans. GAGs accelerate Aβ polymerization4 and increase fibril 
resistance to proteolytic degradation.5 The recent clinical failure 
of drugs that inhibit Aβ aggregation in vitro6 may reflect, in part, 
the role of molecules such as GAGs in the development and stabi-
lization of amyloid in the brain. Work focusing on GAGs has 
revealed a complicated picture of interactions with protein net-
works, with low binding specificity and high redundancy among 
heterogeneous saccharide units7.   
We previously detected a GAG binding site at the surface of fi-
brillar MAβ40 (an Aβ40 homologue with an N-terminal methio-
nine) from heparin-induced peptide chemical shift perturbations 
measured using cross-polarization magic-angle spinning (CP-
MAS) solid-state NMR (SSNMR).8 In this and previous studies, 
heparin was employed as a proxy for the highly sulfated domain 
of heparan sulfate (HS) commonly associated with amyloid 
plaques and sharing the same disaccharide units as heparin.9. 
Aβ40 fibrils are polymorphic and fibril strains having approxi-
mate 2-fold (2A) or 3-fold (3Q) cross-sectional symmetry can be 
selected by seeding and morphologically confirmed by 
SSNMR.8,10 Previously, we developed an assay to quantify hepa-
rin binding which involves sedimentation of bound heparin with 
fibrils, and quantifies unbound heparin by addition of  heparinase 
enzyme, creating a spectroscopically active product.8 We found 
that heparin binds with surprisingly higher affinity to MAβ40 3Q 
fibrils than to MAβ40 2A fibrils, and the SSNMR data suggests 
that heparin recognizes the junctions of the triangular cross-
section that is unique in the structures of 3Q fibrils (Figure S1).8 
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Figure 1. GAG binding to amyloid fibrils. (A) Binding affinities 
of fibrils to low molecular weight heparin (LMWH, dp16). Curves 
were obtained by non-linear least-squares fitting of a Hill func-
tion. (B) Apparent dissociation constants Kd for MAβ40 3Q fibrils 
binding heparin fragments of different degrees of polymerization 
(dp4-dp18). (C) TEM image of 3Q fibrils co-sedimented with [U-
13C]OHA. (D) Chemical structure of [U-13C]OHA.  
Here we show, in addition, that de novo MAβ40 fibrils assembled 
without seeding, a peptide comprised of Aβ residues 16-22 
(KLVFFAE), human amylin (hIAPP) which is 47% similar in 
sequence to Aβ40, and a uniform morphology of MAβ42 fibrils 11 
bind weakly to low-molecular weight heparin (LMWH) (Figure 
1A, Figure S2). These binding differences suggest a unique rela-
tionship between 3Q fibrils in particular and heparin, but the 
origin of this specific relationship requires a full molecular-level 
understanding of the 3Q fibril-heparin interaction. Whether all 
heparin residues lie in contact with specific amino acids (Figure 
S1, top), or whether part of heparin lies away from the fibril sur-
face (Figure S1, bottom) is not known. Here, synthesis of a uni-
formly 13C-labelled octasaccharide heparin analog ([U-13C]OHA) 
has enabled the detailed analysis of a GAG-amyloid interaction 
for the first time from the GAG perspective, using cross-
polarization magic-angle spinning (CP-MAS) SSNMR to observe 
the GAG bound to insoluble 3Q MAβ40 fibrils.   
We assessed the affinities of heparin-derived polysaccharides of 
different length (dp4–dp18) for 3Q-seeded MAβ40 fibrils, using 
the GAG binding assay described above and in Ref. 8 8  All hepa-
rin fragments show saturable binding consistent with specific 
GAG-fibril interactions, and an apparent Bmax of < 20 µM (Figure 
S3, Figure S4). Heparin tetrasaccharide (dp4) shows the lowest 
binding affinity (Kd = 78 µM ±  17 µM) and, although the larger 
fragments show slight increases in binding affinity, there is no 
significant difference between the Kd values for dp6-dp18 (Figure 
1B and Figure S3). An octasaccharide (dp8; Kd = 43 ± 11 µM) 
was chosen therefore as a representative GAG to investigate amy-
loid binding in structural detail. [U- 13C]OHA (synthesized as in 
Ref. 12) consists of alternating 1-4 linked, 6-O-sulfated, N-
sulfated α–D-glucosamine [amino sugar (A)] and 2-O-sulfated α–
L-iduronic acid (I) units, with a 1,6-anhydro ether bridge in the 
terminal iduronate ring (Figure 1D) maintaining a closed ring at 
the former reducing terminus. A 2-fold molar excess of [U-
13C]OHA was added to 15N-labelled MAβ40 fibrils prepared by 
seeding with the 3Q morphology.10 13C spectra of [U-13C]labeled 
seeded fibrils resembled previously published MAβ40 3Q spec-
tra8, verifying the fibril morphology. Transmission electron mi-
croscopy (TEM) confirms that the linear unbranched fibrils are 
maintained (Figure 1C). The fibrils were isolated by centrifuga-  
 
Figure 2. 13C CP-MAS SSNMR spectra of the [U-15N] 3Q fibril-
[U-13C]OHA complex. (A) Experimental spectrum (black) at 4°C, 
with assignments, and a simulated spectrum from the solution 
chemical shifts (red). (B) 2D symmetrized 13C-13C spectrum rec-
orded with a DARR mixing time of 20 ms (black) and an unsym-
metrized spectrum at 50 ms mixing time (red).   
tion and the pellet, estimated to contain 600 nmoles MAβ40 and 
170 nmoles bound [U-13C]OHA, was analysed by 13C CP-MAS 
SSNMR, revealing signature peaks (60-102 ppm) from the octa-
saccharide. Under CP-MAS, signals are detected only from nuclei 
in environments where molecular dynamics are too slow (<104 
Hz) to average the 1H-13C dipolar couplings (e.g. Ref. 14). Hence 
the observed [U-13C]OHA peaks must arise from octasaccharide 
associated with the insoluble fibrils. Although the peaks are too 
broad to resolve residue-specific detail, a two-dimensional 13C-
13C SSNMR spectrum (Figure 2B) and tentative peak assignments 
from a HSQC solution spectrum (Figure S5) enabled resonances 
to be attributed to positions on the glucosamine and iduronate 
residues.  The changes in chemical shifts upon binding are small 
(Table S1), which argues against major conformational perturba-
tions that can result in significant changes in chemical shifts, par-
ticularly if hydrogen bonding is disrupted.13  
The bound saccharide dynamics were assessed further by CP-
MAS NMR.  A 13C refocused INEPT15 SSNMR spectrum at 4 ºC, 
which detects only long-lifetime coherences from highly mobile 
groups, is dominated by peaks from MAβ40 (12-68 ppm), with 
very weak signals from 68-78 ppm that may arise from a small 
mobile fraction of bound or unbound [U-13C]OHA. The absence 
of peaks around 100 ppm from A-1 and I-1 implies that large-
scale motional fluctuations, involving the entire octasaccharide 
backbone, do not occur.  Measurements of motionally-sensitive 
cross-polarization rates RHC and rotating frame relaxation rates 
R1ρH. RHC and R1ρH values for the CH groups at 4°C (Figure 3B; 
original data in Figure S6) are typical of organic solids with re-
stricted molecular dynamics.16 The rates remain essentially the 
same at -25°C, which suggests that the saccharide dynamics are 
similarly impaired in the frozen and non-frozen states.  Increased 
dynamics from -25°C to 4°C (including faster rates of chemical 
exchange between free and bound states) would result in slower 
cross-polarization and relaxation rates (see SI and Figure S7 for 
further discussion).17 Order parameters SCH determined from octa-
saccharide 13C-1H dipolar couplings (Figure S8) are near the rigid-  
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Figure 3. SSNMR analysis of [U-13C]OHA interactions with [U-15N]MAβ40 fibrils. (A) CP-MAS spectrum of fibrils alone (top) overlaid 
with the spectrum from Figure 2A (red) and a refocused INEPT spectrum of the complex of fibrils and [U-13C]OHA (bottom). (B) Cross-
polarization rate constants RHC and proton rotating frame relaxation rates R1ρH of [U-13C]OHA bound to the fibrils. (C) 15N CP-MAS spec-
tra of fibrils alone (top) and with [U-13C]OHA (bottom). Neut=neutral; prot.=protonated; SS= spinning sideband; NT = N-terminal amine. 
(D) 1H-15N HETCOR spectrum. (E, F) Measurements of dipolar couplings between fibrils and [U-13C]OHA at -25°C. (E) Full-echo (S0) 
and dephased-echo (S) 15N{13C}REDOR spectra (8.3-ms dephasing) and difference (). (F) 13C{15N}-FSR spectra (6.4-ms dephasing) 
obtained with selective refocusing applied at the frequencies of 15Nδ1/ε2  and C-1 of [U-13C]OHA (red) and a full-echo spectrum (black).   
limit value of 1.0 and consistent with low-amplitude motions of 
ring C-H bonds on the sub-millisecond time scale. These data 
strongly suggest that all octasaccharide residues are restrained by 
intimate contact with MAβ40.  
We next sought to identify close contacts between [U-15N]MAβ40 
fibrils and [U-13C]OHA. The 15N CP-MAS spectrum of 3Q fibrils 
alone shows sharp peaks from Arg and Lys side-chains and His 
15Nδ1/ε2 resonances (160-180 ppm) that are much broader, possibly 
due to proton exchange or tautomerisation.11The 15N 1D and 1H-
15N HETCOR spectra of the [U-13C]OHA-fibril complex reveal 
the appearance of a new sharp peak at ~161 ppm (Figure 3, C and 
D), reveal several sharper peaks assigned to backbone and 
Asn/Gln amides, which suggests a general ordering of the fibrils 
in the presence of the GAG, and a new sharp peak at ~161 ppm 
attributed to His Nε2. Histidine 15Nε2 and 15Nδ1 chemical shifts for 
model tripeptides are 173-176 ppm for the acidic form (and 
1Hε2/1Hδ1 shifts are > 10 ppm) and ~231 ppm and 181 ppm for the 
conjugate base.18 Here the peak at 161 ppm may reflect the stabi-
lization of protonated His ring(s) by the octasaccharide CO2- and 
SO3- groups. A non-selective 15N-observed, 13C-dephased rota-
tional-echo double-resonance (15N{13C}REDOR) experiment 
(Figure 3E) showed weak dephasing of peptide amide resonances 
(112-130 ppm) and possibly also of His resonances, although the 
signal-to-noise is rather poor. Dipolar dephasing of resonances 
assigned to Arg, Lys and Gly was not observed above the noise. 
Dephasing was not quantified because of uncertainties arising 
from there being a 3-fold excess of fibrils over [U-13C]OHA and 
because of small contributions from 13C at natural abundance.  A 
13C-observed frequency-selective rotational-echo double-
resonance (FSR) experiment19 was used to detect specific 15N-13C 
dipolar interactions between His side-group 15Nδ1/ε2 sites and sac-
charide C-1 carbons in the 97-100 ppm region.  The observed 
dipolar dephasing (S/S0 = 0.72 ± 0.15), corresponds to a 13C-15N 
distance of 3.1-4.6 Å for a single spin pair, consistent with His-[U-
13C]OHA interactions.  The SSNMR measurements provide new 
clues about the selectivity of heparin-derived GAGs for MAβ40 
fibrils with 3Q morphology, and highlight the role of saccharide 
interactions with histidines (H6, H13 and/or H14) in the formation 
of the GAG-3Q fibril complex. We confirmed that GAG sulfate 
moieties are critically important for this interaction by showing 
that fully desulfated heparin does not bind to the fibrils (Figure 
S9A). GAG sulfate groups may thus interact with H6 and H13 if 
the GAG recognizes the junctions of the unique triangular cross-
section of the 3Q morphology, whereas interactions with H14 
would require binding to the outer surface common to both 2A 
and 3Q morphologies (Figures S10, S11).  The higher affinity of 
heparin for 3Q than for 2A fibrils favors the preferential recogni-
tion of the unique junctions of 3Q.  A 3Q-seeded variant of 
MAβ40, H6F, shows reduced heparin binding (Kd = 100 µM ±14 
µM, compared to 43 µM for dp8, Figure S9B, S10), which im-
plies that H6 is involved in, although not essential, for complex 
formation.[U-13C]OHA may bind tightly if its anionic groups are 
oriented approximately parallel to the fibril long axis, allowing 
interactions with polycationic ladders of residues from the repeat-
ing peptide units.  Computational molecular docking of OHA in 
the cleft at the triangular junctions, restrained by a distance of 
<4.0 Å between Nδ1/ε2 sites of appropriate H6 rings in the flexible 
N-terminal region and octasaccharide C-1 positions, allows for 
ionic interactions between sulfate and imdazo groups of H6 and 
H13 on opposite faces (Figure 4A), as well as hydrogen bonding 
with N27 (which previously showed > 1 ppm chemical shift per-
turbations upon heparin binding8), acting in concert to strengthen 
the interaction between peptide and saccharide further. The pres-
ence of Asn residues alongside cationic residues has been posited 
recently as a characteristic of GAG binding sites in proteins.20 The 
octasaccharide in a broadly linear conformation bears O- and N-
linked SO3- groups that match approximately the periodicity of 
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repeating side groups (~4.7 Å) (Figure 4B). This, and our binding 
data on other fibril types (Figure 1A) suggest that GAG-3Q inter-
actions are more specific than mere electrostatic patterning. In-
stead, the structure of the 3Q fibril corners localizes multiple 
charged and hydrogen bonding residues in a favorable orientation, 
providing a tight and specific binding site for heparin (Figure 
S11). The involvement of histidine residues in this interaction 
suggests that disease states manifesting local pH changes could 
enhance GAG-fibril interactions, leading to altered rates of dis-
ease progression. Fibrils with different binding modes and affini-
ties may rationalize the array of phenotypes that are present in AD 
and the range of timescales over which the disease progresses.   
 
Figure 5. Model of [U-13C]OHA binding to MAβ40 fibrils. (A) 
Cross-sectional view of the 3Q fibril, from 2lmq.pdb (negative 
stagger, with 9 flexible N-terminal residues added) viewed down 
the fibril axis (z) and highlighting key binding residues and OHA 
(purple spheres) docked in one of the three cleft sites. (B) View of 
an octasaccharide molecule with repeating H6 and N27 residues.   
The work presented provides the first glimpse of a GAG chain 
binding tightly and offers rationalization for the quantifiable and 
surprisingly specific affinity for a well-defined morphology of 
Aβ40 fibrils. A three-fold conformation of Aβ has been isolated 
and purified from human brain tissue, underscoring the relevance 
of this structural motif in disease2.   These results reveal that while 
GAGs are commonly found associated with amyloid plaques, 
GAG-fibril interactions show remarkable specificity which may 
influence the varied properties of amyloid fibrils in disease. 
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